US Stock MarketDetailed Quotes

INAB In8bio

Watchlist

0.310
+0.005+1.64%

Trading Dec 11 14:00 ET

22.47MMarket Cap-0.42P/E (TTM)

In8bio Stock Forum

Trytosaveabit

Dec 10 06:08

Update

$In8bio (INAB.US)$ IN8bio Reports No New Deaths or Relapses in Phase 1 Trial of Gamma-Delta T Cell Therapy
Benzinga· 1 min ago
IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced updated data from the ongoing Phase 1 trial of INB-100, an allogeneic, haploidentical gamma-delta T cell therapy in older patients with hematologic malignancies undergoing haploidentical stem cell transplant (HSCT) with reduced i...

Jaguar8

Dec 10 06:00

NEWS

$In8bio (INAB.US)$
IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting
Tuesday, 10th December at 7:00 am
• INB-100 continues to demonstrate durable complete remissions (CR) with no relapses observed in any acute myeloid leukemia (AML) patients including those with high-risk disease after a median follow-up of 19.7 months.
• Data highlights ...

Hmm

NEWS

$In8bio (INAB.US)$
IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting
IN8bio presented results from their fully enrolled Phase 1 trial of INB-200 at the Society for Neuro-Oncology Annual Meeting. 50% of patients receiving repeated doses (n=10) remained alive and in remission beyond expected median overall survival, while single-dose patients (n=3) did not achieve this outcome. The trial de...